6533b822fe1ef96bd127d5f1

RESEARCH PRODUCT

Biomarkers as Prognostic, Predictive, and Surrogate Endpoints

Marta CastigliaFrancesco PassigliaGiuseppe CiceroViviana Bazan

subject

Oncologymedicine.medical_specialtyGiSTSurrogate endpointbusiness.industryColorectal cancerCancerDiseasemedicine.diseaseCirculating tumor cellInternal medicinemedicineStromal tumorLiquid biopsybusiness

description

The improved understanding of tumor biology associated with the recent technological advancement has revealed a growing number of potential tumor biomarkers as candidate for clinical use, providing new opportunities for improving the management of cancer patients in all phases of care. Biomarkers have several clinical applications in oncology, including risk assessment for disease recurrence or early diagnosis in healthy population. After the advent of targeted therapies, a growing interest has been focused on their potential role as prognostic, predictive, and surrogate endpoints, in order to promote personalized strategies. The introduction of molecular biomarkers in clinical practice has radically changed the natural history of some tumors, including gastrointestinal stromal tumor (GIST), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and melanoma, allowing many patients to receive an individualized treatment. Liquid biopsies and the use of circulating biomarker represent the new perspective of the oncological scientific community, with very promising implications in the clinical management of cancer patients.

yearjournalcountryeditionlanguage
2015-01-01
https://doi.org/10.1007/978-1-4939-2047-1_4